Calculation of intraocular lens power after trabeculectomy

Belov, D.F.; Nikolaenko, Vadim P.

doi:10.17116/oftalma202113706161

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biological ultrasound microscopy revealed that the thickness of the iris, ciliary body, and suspensory ligament did not change significantly after IOL implantation. However, the depth of the anterior chamber increased, indicating that the IOL replaced the eye's hypertrophic lens, and the iris regained its flat shape without contacting the IOL [ 11 ]. According to some studies, the IOP control rate was low in patients with glaucoma who were followed for nine months after IOL [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Meta-Analysis of the Comprehensive Efficacy of Intraocular Lens Implantation in Glaucoma Patients

Zhou

2022

BioMed Research International

View full text Add to dashboard Cite

This study is aimed at investigating the efficacy of intraocular lens (IOL) implantation in patients suffering from glaucoma through meta-analysis of the previously published research. For this purpose, different literature databases were searched for identification of clinical studies published between January 2000 and January 2022 on evaluating IOL’s efficacy in treating glaucoma. RevMan 5.3 was used to conduct a meta-analysis of the pertinent data. The central anterior chamber depth (ACD), corneal endothelial cell counts, best-corrected visual acuity (BCVA), intraocular pressure (IOP), anti-glaucoma medications (AGM), and axial length (AL) changes were compared, and the incidence of postoperative complications was thoroughly evaluated. The Cochran chi-square test was used to examine the heterogeneity of the evaluation results. According to the inclusion and exclusion criteria, 20 studies included 948 glaucomatous eyes. IOP was significantly lower than before treatment ( MD = 8.64 , 95 CI: 5.75-11.53; Z = 5.86 , P < 0.0001 ), while ACD increased significantly ( MD = − 1.38 , 95 percent CI: -1.74-1.02; Z = 7.49 , P < 0.0001 ). The corneal endothelial cell counts were homogeneous ( MD = 225.08 , 95% CI: -64.17 to -514.33; Z = 1.53 , P = 0.20 ). AGM utilisation decreased ( MD = 1.43 , 95% CI: 0.752.12, Z = 4.09 , P < 0.0001 ). AL decreased significantly ( MD = 0.31 ; 95% CI: 0.09-0.54; Z = 2.71 ; P = 0.007 ). The incidence of complications remained insignificant after IOL treatment ( OR = 1.05 , 95% CI: 0.42 to 2.60; Z = 0.10 , P = 0.92 ; P = 0.92 ). These findings indicate that IOL treatment can significantly reduce intraocular pressure, glaucoma drug use, and aqueous level (AL) in glaucoma patients while increasing the depth of the central anterior chamber. This study offers a theoretical foundation for selecting glaucoma treatment methods.

show abstract

Section: Introductionmentioning

confidence: 99%

Meta-Analysis of the Comprehensive Efficacy of Intraocular Lens Implantation in Glaucoma Patients

Zhou

2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In summary, biometric changes may occur after trabeculectomy surgery and should be a consideration in patients undergoing phacotrabeculectomy or standalone cataract surgery after prior trabeculectomy. AL, ACD, and keratometry are primary determinants in IOL power calculations; hence, post-operative changes in these biometric measurements may lead to increased risk of post-operative refractive surprise and IOL power calculation errors [ 127 , 138 ], although some studies have demonstrated that post-phacotrabeculectomy AL and keratometric changes may effectively negate each other’s effect [ 139 ]. Standalone cataract surgeries performed much later (at least 3–6 months [ 118 ]) after initial trabeculectomy surgery may allow refractive outcomes and ocular measurements to stabilize, thereby not precluding the use of premium IOLs (particularly toric IOLs) in these patients.…”

Section: Discussion: Considerations In Premium Iol Implantation In Gl...mentioning

confidence: 99%

Premium Intraocular Lenses in Glaucoma—A Systematic Review

Hong,

Ang,

Dorairaj

et al. 2023

Bioengineering

View full text Add to dashboard Cite

The incidence of both cataract and glaucoma is increasing globally. With increasing patient expectation and improved technology, premium intraocular lenses (IOLs), including presbyopia-correcting and toric IOLs, are being increasingly implanted today. However, concerns remain regarding the use of premium IOLs, particularly presbyopia-correcting IOLs, in eyes with glaucoma. This systematic review evaluates the use of premium IOLs in glaucoma. A comprehensive search of the MEDLINE database was performed from inception until 1 June 2023. Initial search yielded 1404 records, of which 12 were included in the final review of post-operative outcomes. Studies demonstrated high spectacle independence for distance and good patient satisfaction in glaucomatous eyes, with positive outcomes also in post-operative visual acuity, residual astigmatism, and contrast sensitivity. Considerations in patient selection include anatomical and functional factors, such as the type and severity of glaucomatous visual field defects, glaucoma subtype, presence of ocular surface disease, ocular changes after glaucoma surgery, and the reliability of disease monitoring, all of which may be affected by, or influence, the outcomes of premium IOL implantation in glaucoma patients. Regular reviews on this topic are needed in order to keep up with the rapid advancements in IOL technology and glaucoma surgical treatments.

show abstract

Calculation of intraocular lens power after trabeculectomy

Cited by 2 publications

References 25 publications

Meta-Analysis of the Comprehensive Efficacy of Intraocular Lens Implantation in Glaucoma Patients

Meta-Analysis of the Comprehensive Efficacy of Intraocular Lens Implantation in Glaucoma Patients

Premium Intraocular Lenses in Glaucoma—A Systematic Review

Contact Info

Product

Resources

About